BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Farkas P, Csuka D, Mikes B, Sinkovits G, Réti M, Németh E, Rácz K, Madách K, Gergely M, Demeter J, Prohászka Z. Complement activation, inflammation and relative ADAMTS13 deficiency in secondary thrombotic microangiopathies. Immunobiology 2017;222:119-27. [DOI: 10.1016/j.imbio.2016.10.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Sweeney JM, Barouqa M, Krause GJ, Gonzalez-Lugo JD, Rahman S, Gil MR. Low ADAMTS13 Activity Correlates with Increased Mortality in COVID-19 Patients. TH Open 2021;5:e89-e103. [PMID: 33709050 DOI: 10.1055/s-0041-1723784] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
2 Yang J, Wu Z, Long Q, Huang J, Hong T, Liu W, Lin J. Insights Into Immunothrombosis: The Interplay Among Neutrophil Extracellular Trap, von Willebrand Factor, and ADAMTS13. Front Immunol 2020;11:610696. [PMID: 33343584 DOI: 10.3389/fimmu.2020.610696] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
3 Kishimoto K, Hasegawa D, Kawasaki K, Tamura A, Yamamoto N, Saito A, Kozaki A, Ishida T, Kosaka Y. Early posttransplant plasma ADAMTS13 activity reduction in stem cell transplantation: a prospective study of 46 pediatric patients. Bone Marrow Transplant 2019;54:1926-9. [PMID: 30890772 DOI: 10.1038/s41409-019-0506-4] [Reference Citation Analysis]
4 Becker RC, Sexton T, Smyth SS. Translational Implications of Platelets as Vascular First Responders. Circ Res 2018;122:506-22. [PMID: 29420211 DOI: 10.1161/CIRCRESAHA.117.310939] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 9.7] [Reference Citation Analysis]
5 Martinelli N, Montagnana M, Pizzolo F, Friso S, Salvagno GL, Forni GL, Gianesin B, Morandi M, Lunardi C, Lippi G, Polati E, Olivieri O, De Franceschi L. A relative ADAMTS13 deficiency supports the presence of a secondary microangiopathy in COVID 19. Thromb Res 2020;193:170-2. [PMID: 32707276 DOI: 10.1016/j.thromres.2020.07.034] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 14.5] [Reference Citation Analysis]
6 Masias C, Cataland SR. The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis. Blood 2018;132:903-10. [PMID: 30006329 DOI: 10.1182/blood-2018-02-791533] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
7 Matsumoto H, Takeba J, Umakoshi K, Kikuchi S, Ohshita M, Annen S, Moriyama N, Nakabayashi Y, Sato N, Aibiki M. ADAMTS13 activity decreases in the early phase of trauma associated with coagulopathy and systemic inflammation: a prospective observational study. Thromb J 2021;19:17. [PMID: 33712048 DOI: 10.1186/s12959-021-00270-1] [Reference Citation Analysis]
8 Trojnar E, Józsi M, Szabó Z, Réti M, Farkas P, Kelen K, Reusz GS, Szabó AJ, Garam N, Mikes B, Sinkovits G, Mező B, Csuka D, Prohászka Z. Elevated Systemic Pentraxin-3 Is Associated With Complement Consumption in the Acute Phase of Thrombotic Microangiopathies. Front Immunol 2019;10:240. [PMID: 30858847 DOI: 10.3389/fimmu.2019.00240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Masias C, Vasu S, Cataland SR. None of the above: thrombotic microangiopathy beyond TTP and HUS. Blood 2017;129:2857-63. [PMID: 28416509 DOI: 10.1182/blood-2016-11-743104] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
10 Dixon BP, Gruppo RA. Atypical Hemolytic Uremic Syndrome. Pediatric Clinics of North America 2018;65:509-25. [DOI: 10.1016/j.pcl.2018.02.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
11 Oh J, Oh D, Lee SJ, Kim JO, Kim NK, Chong SY, Huh JY, Baker RI; Korean TTP Registry Investigators. Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura. Blood Res 2019;54:218-28. [PMID: 31730685 DOI: 10.5045/br.2019.54.3.218] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
12 Horváth O, Kelen K, Prohászka Z, Hosszú Á, Szabó AJ, Reusz GS. Atypical HUS and Crohn's disease-interference of intestinal disease activity with complement-blocking treatment. Pediatr Nephrol 2021. [PMID: 34328541 DOI: 10.1007/s00467-021-05167-9] [Reference Citation Analysis]
13 Henry BM, Szergyuk I, de Oliveira MHS, Lippi G, Benoit JL, Vikse J, Benoit SW. Complement levels at admission as a reflection of coronavirus disease 2019 (COVID-19) severity state. J Med Virol 2021;93:5515-22. [PMID: 33974276 DOI: 10.1002/jmv.27077] [Reference Citation Analysis]